Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Top Cited Papers
- 12 December 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 19 (1), 65-75
- https://doi.org/10.1016/s1470-2045(17)30909-9
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experienceBlood, 2016
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyThe Lancet Oncology, 2016
- Targeted therapies for CLL: Practical issues with the changing treatment paradigmBlood Reviews, 2015
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2015
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaJAMA Oncology, 2015
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinibBlood, 2015
- Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing ClinicianJournal of Clinical Oncology, 2014
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2014
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibNew England Journal of Medicine, 2014
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013